Ziccum reports on developments in the portfolio of industry partner projects

Several new dialogues have been initiated, involving different types of drug modalities to be tested with LaminarPace technology. A broader pipeline including several customer and therapeutic segments increases the business potential for Ziccum and significantly reduces the risk taking the technology to market.

One Big Pharma collaboration has reached the readout stage, and is subject to further evaluation, while one new dialogue has emerged, and one is in final negotiation for a paid study.

The mRNA/LNP Field

• For mRNA/LNP projects, where Ziccum has generated very important data recently, more advanced discussions now include one more US Biotech Corporation (Biotech IV) where feasibility study negotiations are reaching final stages; the parties have agreed on the scope of the work plan and are currently reviewing legal terms. The modality to be tested is mRNA in a partner specific LNP formulation, where organ targeting is an extra technology edge for the mRNA/LNP partner portfolio.

• The Big Pharma II Feasibility study, signed in July 2023, has reached completion and readout stage. Ziccum can report very good results for the technical parameters: encapsulation efficiency as well as LNP particle size and size distribution.

While the first part of this joint project has been completed, the Big Pharma II is currently assessing whether to initiate the second step.

• The Feasibility study with Biotech Corp II achieved excellent results in first quarter 2024 as previously reported. The partner has not taken any decision for next potential steps as of yet.

Protein subunit vaccines

• The Biotech Corp V dialogue has progressed, where the partner is planning to propose the scope for a Feasibility study within short. As Ziccum’s organization has very good knowledge in the field of subunit vaccines, it may be a welcome addition to the project portfolio and would provide further scientific support for the LaminarPace technology.

Lentivirus vaccines

• The US-based CDMO Partner (CDMO I) project is currently on pause as communicated in the Q1 report, with the partner assessing which application may be utilized, to best achieve competitive advantages of the LaminarPace technology. There is great enthusiasm for Ziccum’s disruptive technology in the partner organization.

Protein Biopharmaceuticals

There are several new Big Pharma dialogues with large industry players having approached Ziccum recently. This has resulted in large forum presentations of the LaminarPace technology to scientific teams mainly in the UK, US and Sweden, and new project opportunities in review.

• One of these partners, Big Pharma III has proposed a joint Feasibility project for testing of a protein pharmaceutical modality with LaminarPace, and to jointly make a scientific publication with Ziccum. Big Pharma III has important resources in vaccines as well as in therapeutics. This fruitful dialogue has progressed rapidly and is new to the Portfolio overview.

Ziccum’s CEO Ann Gidner: “We are delighted to keep on broadening our business scope with further serious industry dialogues with top class partners in Biotech and Big Pharma. The LaminarPace technology is here to solve the significant practical problems when advancing new biological modalities into real patient treatments – and the need for solutions is getting more into industry focus every day. In coming months, we hope to progress our collaborative pipeline further, while maintaining awareness of and respect for the many complex judgements needed when implementing new, unique technology in pharmaceutical development.

Ziccum Portfolio overview as of May 31st attached.